Clinical Assistant Professor, Department of Medicine
Saud Alsubait, MD, is a board-certified medical oncologist with Ascension Borgess Cancer Center in Kalamazoo, Michigan. He earned his medical degree from the University of Dammam, Saudi Arabia. He completed his residency in internal medicine and obtained fellowship training in hematology and medical oncology at Michigan state university. At MSU, he taught and trained medical students and residents as a clinical instructor. He also served as chief fellow at the hematology and medical oncology fellowship program. His clinic, teaching, and research interest include lung and genitourinary cancers.
Education and Training
- Clinical Fellowship 2021, Hematology and Oncology, Michigan State University College of Human Medicine
- Residency 2018, Internal Medicine, Connecticut Institute for Communities, Greater Danbury Community Health Center
- Residency 2012, Radiology, King Saud bin Abdulaziz University for Health Sciences
- MBBS 2009, College of Medicine, University of Dammam
- Medical Oncology
Alsubait S. Lenvatinib plus pembrolizumab improves outcomes in previously untreated advanced clear cell renal cell carcinoma Journal of Clinical Outcomes Management. 2021;28(2):54-56.
Alsubait S., Isaac D. Oral Relugolix Yields Superior Testosterone Suppression and Decreased Cardiovascular Events Compared with GnRH Agonist Journal of Clinical Outcomes Management. 2020;27(4):153-156.
Nassereddine S., Alsubait S., Tabbara I. Sinusoidal obstruction syndrome (Veno-occlusive disease) following hematopoietic stem cell transplant: Insights and therapeutic advances Anticancer Research. 2018;38(5):2597-2605.